{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:29:49Z","timestamp":1770748189041,"version":"3.49.0"},"reference-count":13,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Psoriasis is a chronic inflammatory skin disease requiring long-term\ntreatment. However, there are approximately 71 million individuals with chronic HCV infection\nworldwide. In psoriatic patients affected by chronic HCV infection, conventional systemic drugs\nmay be frequently contraindicated, while data on biologics use are limited.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case presentation:<\/jats:title>\n<jats:p>The case of a 48-year-old Caucasian man suffering from a severe form of\nplaque psoriasis and affected by a chronic-HCV-infection treated with guselkumab has been reported.\nDespite a huge improvement of the skin lesions (PASI reduced from 18 to 2), guselkumab\nwas discontinued due to an HCV-infection reactivation after 3 months of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>To the best of our knowledge, this is the first case report of the use of guselkumab in\nan HCV psoriatic patient. Further studies are needed to evaluate the safety of guselkumab in chronic\nHCV patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220307112926","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T06:27:03Z","timestamp":1646720823000},"page":"390-392","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient\nTreated with Guselkumab"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":true,"given":"Angelo","family":"Ruggiero","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Gallo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Patr\u00ec","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"Gisondi P.","year":"2017","unstructured":"Gisondi P.; Altomare G.; Ayala F.; Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017,31(5),774-790","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"Pawlotsky J.M.","year":"2018","unstructured":"Pawlotsky J.M.; Negro F.; Aghemo A.; European Association for the Study of the Liver (EASL) recommendations on treatment of hepatitis C 2018. J Hepatol 2018,69,461-511","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","volume":"22","author":"Bonifati C.","year":"2016","unstructured":"Bonifati C.; Lora V.; Graceffa D.; Nosotti L.; Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016,22(28),6444-6455","journal-title":"World J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","volume":"20","author":"Piaserico S.","year":"2019","unstructured":"Piaserico S.; Messina F.; Russo F.P.; Managing psoriasis in patients with HBV or HCV infection: Practical considerations. Am J Clin Dermatol 2019,20(6),829-845","journal-title":"Am J Clin Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.12045","volume":"168","author":"Navarro R.","year":"2013","unstructured":"Navarro R.; Vilarrasa E.; Herranz P.; Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting. Br J Dermatol 2013,168(3),609-616","journal-title":"Br J Dermatol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaad.2021.01.025","volume":"85","author":"Ruggiero A.","year":"2021","unstructured":"Ruggiero A.; Fabbrocini G.; Cinelli E.; Megna M.; Guselkumab and risankizumab for psoriasis: A 44-week indirect real-life comparison. J Am Acad Dermatol 2021,85(4),1028-1030","journal-title":"J Am Acad Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1800577","author":"Megna M.","year":"2020","unstructured":"Megna M.; Fabbrocini G.; Cinelli E.; Camela E.; Ruggiero A.; Guselkumab in moderate to severe psoriasis in routine clinical care: An Italian 44-week real-life experience. J Dermatolog Treat 2020,1-5","journal-title":"J Dermatolog Treat"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e14673","DOI":"10.1111\/dth.14673","volume":"34","author":"Ruggiero A.","year":"2021","unstructured":"Ruggiero A.; Fabbrocini G.; Cinelli E.; Megna M.; Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther 2021,34(1),e14673","journal-title":"Dermatol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e14144","DOI":"10.1111\/dth.14144","volume":"33","author":"Megna M.","year":"2020","unstructured":"Megna M.; Fabbrocini G.; Ruggiero A.; Cinelli E.; Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12\/23 and\/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol Ther 2020,33(6),e14144","journal-title":"Dermatol Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"13030\/qt47h636rx","DOI":"10.5070\/D32510045827","volume":"25","author":"Duncan JR","year":"2019","unstructured":"Duncan JR; Orlowski TJ; Elewski BE; Safety of guselkumab in hepatitis B virus infection. Dermatol Online J 2019,25(10),13030\/qt47h636rx","journal-title":"Dermatol Online J"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/ijms17071070","volume":"17","author":"Meng P.","year":"2016","unstructured":"Meng P.; Zhao S.; Niu X.; Involvement of the interleukin-23\/interleukin-17 axis in chronic hepatitis C virus infection and its treatment re-sponses. Int J Mol Sci 2016,17(7),1070","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e21000","DOI":"10.5812\/hepatmon.21000","volume":"14","author":"Ashrafi Hafez A.","year":"2014","unstructured":"Ashrafi Hafez A.; Ahmadi Vasmehjani A.; Baharlou R.; Analytical assessment of interleukin - 23 and -27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a). Hepat Mon 2014,14(9),e21000","journal-title":"Hepat Mon"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1128\/JVI.03376-12","volume":"87","author":"Wang J.M.","year":"2013","unstructured":"Wang J.M.; Shi L.; Ma C.J.; Differential regulation of interleukin-12 (IL-12)\/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection. J Virol 2013,87(8),4372-4383","journal-title":"J Virol"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220307112926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201812\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220307112926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:55:25Z","timestamp":1667469325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201812\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220307112926","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}